Market Place
Sourcing Support
Elicio Therapeutics Reports Inducement Grants
16 Jan 2026 //
GLOBENEWSWIRE
Elicio Therapeutics Virtual KOL Event on June 25, 2025
17 Jun 2025 //
GLOBENEWSWIRE
Elicio Therapeutics Reports 2024 Financial Results & Updates
31 Mar 2025 //
GLOBENEWSWIRE
Elicio Therapeutics Appoints Preetam Shah as CFO and CSO
24 Mar 2025 //
GLOBENEWSWIRE
Elicio Therapeutics Prices $11.5M Underwritten Public Offering
28 Jun 2024 //
GLOBENEWSWIRE
Elicio Announces Disease-Free Survival from the Ongoing AMPLIFY-7P Phase 1a
27 Jun 2024 //
GLOBENEWSWIRE
Elicio Therapeutics Announces Proposed Public Offering
27 Jun 2024 //
GLOBENEWSWIRE
Elicio Therapeutics Reports Inducement Grants
18 Jun 2024 //
GLOBENEWSWIRE
Elicio Therapeutics Reports Q1 2024 Results, Corporate Updates
15 May 2024 //
GLOBENEWSWIRE
Elicio Therapeutics to Data on ELI-007 and ELI-008 at the AACR Annual Meeting
05 Apr 2024 //
GLOBENEWSWIRE
Elicio Reports 2023 Financial Results and Provides Corporate Updates
29 Mar 2024 //
GLOBENEWSWIRE
Elicio Therapeutics Announces $6.0 Million Private Placement Financing
18 Mar 2024 //
GLOBENEWSWIRE
Elicio Therapeutics Announces Upcoming Presentations at the AACR Annual Meeting
06 Mar 2024 //
GLOBENEWSWIRE
Elicio Therapeutics to Present at the Oppenheimer 34th Annual Conference
05 Feb 2024 //
GLOBENEWSWIRE
Elicio to Present at the B. Riley Securities 4th Annual Oncology Conference
16 Jan 2024 //
GLOBENEWSWIRE
Why Is Elicio Therapeutics (ELTX) Stock Up 11% Today?
09 Jan 2024 //
PRESS RELEASE
Elicio Therapeutics Announces $7.0 Million Private Placement Financing
22 Dec 2023 //
GLOBENEWSWIRE
Elicio Therapeutics to Present at H.C. 4th Annual Precision Oncology Conference
04 Dec 2023 //
GLOBENEWSWIRE
Elicio Therapeutics Reports Third Quarter 2023 Financial Results
09 Nov 2023 //
GLOBENEWSWIRE
Elicio Therapeutics Announces Upcoming Presentations at SITC
11 Oct 2023 //
GLOBENEWSWIRE
Elicio to Present at H.C. Wainwright 25th Annual Global Investment Conference
06 Sep 2023 //
GLOBENEWSWIRE
Elicio Therapeutics Reports Inducement Grants
22 Aug 2023 //
GLOBENEWSWIRE
Elicio Therapeutics Reports Second Quarter 2023 Financial Results
11 Aug 2023 //
GLOBENEWSWIRE
Elicio Therapeutics Reports Inducement Grant to New Chief Financial Officer
02 Jun 2023 //
GLOBENEWSWIRE
Elicio Therapeutics Announces Completion of Merger with Angion Biomedica
01 Jun 2023 //
GLOBENEWSWIRE
Elicio Therapeutics Enters Into Merger Agreement with Angion Biomedica
17 Jan 2023 //
BIOSPACE
Elicio Therapeutics Announces Publication of Preclinical Data in Science
04 Oct 2022 //
GLOBENEWSWIRE
Elicio Therapeutics Receives $2.8 Million Grant from the (GIRF)
20 Sep 2022 //
GLOBENEWSWIRE
Elicio Therapeutics Announces Publication of Preclinical Data on ELI-005
07 Sep 2022 //
GLOBENEWSWIRE
Elicio`s PC Data on Lymph Node-Targeted SARS-CoV-2 Amphiphile Vaccine, ELI-005
06 Jul 2022 //
GLOBENEWSWIRE
Elicio Tx Presents PC Data on AMP-CpG Adjuvant in Combination with EBV Vaccine
06 Jul 2022 //
GLOBENEWSWIRE
Elicio Shows Design of Ongoing AMPLIFY-201 Study in Mutant KRAS-Driven Cancers
27 May 2022 //
GLOBENEWSWIRE
Elicio Announces Publication of Preclinical Data Showing AMP-Peptide Vaccine
23 May 2022 //
GLOBENEWSWIRE
Elicio Therapeutics Enters Clinical Supply Agreement with Regeneron
16 May 2022 //
CONTRACTPHARMA
Elicio Appoints Joy Seymour as VP, Head of RA and Dr. Peter DeMuth to CSO
12 May 2022 //
GLOBENEWSWIRE
Elicio Presents Preclinical Data on the AMP-Peptide Vaccine + TCR-T Cell Therapy
29 Apr 2022 //
GLOBENEWSWIRE
Elicio Tx Presents Updated PC Data at Vaccines Summit Boston 2022 on ELI-005
29 Mar 2022 //
GLOBENEWSWIRE
Elicio Tx Presents Preclinical Data on its Amphiphile-CpG Adjuvant
23 Mar 2022 //
GLOBENEWSWIRE
Elicio Tx Moves into Boston`s Seaport District and Provides Update on Programs
15 Mar 2022 //
GLOBENEWSWIRE
Elicio Presents Preclinical Data on AMP TCR-T and CAR-T Combination Therapies
12 Nov 2021 //
GLOBENEWSWIRE
Elicio Therapeutics Announces First Patient Dosed in the ELI-002 (AMPLIFY-201)
06 Oct 2021 //
GLOBENEWSWIRE
Elicio Therapeutics Presents Updated Preclinical Data on ELI-005
22 Sep 2021 //
GLOBENEWSWIRE
Elicio Announces Virtual Presentation of Data on its Amphiphile-CpG Adjuvant
17 Sep 2021 //
GLOBENEWSWIRE
Elicio Announces Initiation of Its Phase 1/2 Dose-Escalation Study of ELI-002
07 Jul 2021 //
PRESS RELEASE
Elicio Announces Initiation of Its Phase 1/2 Dose-Escalation Study of ELI-002
07 Jul 2021 //
PRESS RELEASE
MEI Pharma Appoints Tina C. Beamon, J.D., as Chief Compliance Officer
07 Jul 2021 //
PR NEWSWIRE
Elicio Announces Initiation of Its Phase 1/2 Dose-Escalation Study of ELI-002
29 Jun 2021 //
GLOBENEWSWIRE
Cancer biotech Elicio Therapeutics files for a $10 million IPO
29 Jun 2021 //
RENAISSANCECAPITAL
Elicio Announces FDA Clearance of IND Application for ELI-002 -- A Therapeutic
23 Feb 2021 //
BUSINATSSWIRE
Elicio Therapeutics Secures a Total of $73 Million in Series B Financing
17 Feb 2021 //
BUSINESSWIRE
Science Advances: Elicio Therapeutics’ SARS-CoV-2 Vaccine Demonstrates T Cell
05 Feb 2021 //
BUSINESSWIRE
Elicio Announces Poster Presentation at 2020 Society for Immunotherapy
10 Nov 2020 //
BUSINESSWIRE
Elicio Therapeutics and Moffitt Collaborate to Study AMP-CD19+CD19 CAR T Cells
16 Sep 2020 //
BUSINESSWIRE
Elicio Therapeutics and National Cancer Institute Collaborate to Study ELI-002
16 Apr 2020 //
BUSINESSWIRE
Elicio`s to Discuss Novel Lymph Node Vaccine Targeting Seven Key mKRAS
19 Feb 2020 //
BUSINESSWIRE
Elicio`s & Natera To Collaborate in Ph I/II Pancreatic Cancer Study of ELI-002
11 Feb 2020 //
BUSINESSWIRE
